Answers are grounded in this paper and cite their sources.
Metastatic colorectal cancer with microsatellite instability (MSI) occurs in approximately 5 % of cases, which is significantly lower than in localized stages (15 %). MSI leads to the accumulation of a large number of mutations and neoantigens on the surface of tumor cells, thereby increasing tumor immunogenicity and determining the efficacy of immune checkpoint inhibitors. According to the results of the KEYNOTE-177 trial, the use of pembrolizumab as first-line therapy for MSI metastatic colorectal cancer statistically significantly increased the median progression-free survival to 16.5 months compared with 8.2 months with standard chemotherapy plus bevacizumab or cetuximab, while grade ≥ 3 adverse events were reported considerably less frequently (22 % vs. 66 %). This article describes a clinical case of a 67-year-old female patient with pT3N2 colon adenocarcinoma (MSI, KRAS G12D mutation, NRAS and BRAF wild-type), in whom disease progression in the form of hepatic and pulmonary metastases was detected one month after completion of 8 cycles of adjuvant chemotherapy according to the XELOX regimen (oxaliplatin + capecitabine). In August 2021, immunotherapy with pembrolizumab 400 mg once every 42 days was initiated. After 12 cycles, complete regression of metastatic lesions in the liver and lungs was achieved. A total of 26 cycles of immunotherapy were administered; in May 2024, given the sustained complete response and a treatment duration exceeding 2.5 years, immunotherapy was discontinued. During the course of treatment, hypothyroidism developed, which was compensated by levothyroxine replacement therapy. According to follow-up examination data from July 2026, the complete response is maintained, the duration of complete response exceeds 3 years, and the treatment-free interval is more than 1.5 years. This case demonstrates the possibility of achieving a durable response to pembrolizumab immunotherapy in patients with MSI metastatic colorectal cancer that is sustained following treatment completion. Further studies aimed at identifying additional predictive biomarkers are needed to optimize the choice between mono- and combination immunotherapy in this category of patients.
No takes yet. Share an insight, caveat, or question.
Chekini et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: